AVI BioPharma, Inc. Announces Positive Pre-Clinical Study Results Presented at the 26th Annual Meeting of the American Society for Virology
PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), announced today the results of five pre-clinical studies using NEUGENE® antisense against a variety of viral diseases. The results were discussed this week at the 26th Annual Meeting of the American Society for Virology at Oregon State University (OSU) in Corvallis, Ore, July 14–18, 2007.